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Meeting Summary
The 18th Annual Meeting of the 
European Lipoprotein Club
W. Armstrong
Pascale Benlian, Armin Steinmetz
he European Lipoprotein Club met September 
11th to the 14th, 1995, in Tutzing, Germany. 
There were 101 participants from 12 European 
countries and the United States. Warren J. Strittmatter 
(Durham, NC) opened the meeting with a state-of-the-art 
lecture on “Apolipoprotein E and Alzheimer’s Disease.” 
Inheritance of specific apoE alleles in large part deter­
mines the risk and mean age of onset of late-onset and 
sporadic AD. Patients with late-onset AD have a higher 
probability of having the APOE4 allele (50% at age 75 
years), whereas the APOE2 allele is associated with a 
later age of onset. Dr Strittmatter discussed the possible 
mechanisms whereby apoE isoforms contribute differ­
ently to disease expression. In his opinion, identifying the 
isoform-specific pathways of apoE metabolism is central 
to the development and testing of hypotheses on the 
pathogenesis of AD.
Isoform-specific differences have been identified in the 
binding of apoE to the MAP-t, which forms paired helical 
filaments and neurofibrillary tangles, and to /5-amyloid 
peptide, a major component of the neuritic plaque. An un­
resolved issue of great importance is the relationship be­
tween structural pathological lesions and the cellular 
pathogenesis responsible for the major signs and symp­
toms of disease, namely, progressive dementia. Identifi­
cation of apoE in the cytoplasm of human neurons and 
characterization of isoform-specific binding of apoE to the 
MAP-t and MAP-2 present the possibility that apoE may 
affect microtubule function in the brain of AD patients. Dr 
Strittmatter concluded his presentation with a report on 
studies that have found differences in the cross-linking of 
apoE isoforms to lipid peroxidation products in vitro 
(apoE3>apoE4); in cerebrospinal fluid these products also 
cross-link with apoE. In the lively discussion that followed, 
Dr Strittmatter defined the use of apoE genotyping in AD 
(1) as a diagnostic tool to confirm AD and (2) for risk 
analysis in a person without clinically evident AD.
The first session on “Novel Functions of Apolipopro- 
teins and Lipoprotein Receptors” began with an excellent 
talk by Wolfgang J. Schneider (Vienna, Austria), during 
which he summarized new findings from his laboratory 
on the molecular genetics of lipoprotein receptor expres­
sion in the laying hen model. These findings place the 
LD LR  gene family at the crossroads of lipoprotein me-
Correspondence to Dr A.F.H. Stalenhoef, Department of Medi­
cine, Division of General Internal Medicine, University Hospital Nij­
megen, PO Box 9101, 6500 HB Nijmegen, Netherlands. 
(Arterioscler Thromb Vase Biol. 1996;16:898-904.)
© 1996 American Heart Association, Inc.
tabolism and cell differentiation. Deposition of yolk li­
poproteins into chicken oocytes is mediated by a receptor 
that belongs to the VLDLR  subgroup of the LD LR  super­
gene family (Bujo et al. EMBO J. 1994;13:5165-5175.). 
Recent additional characterization of the details of this 
receptor, termed OVR, has revealed other surprising fea­
tures. First, a splice-variant form that contains an addi­
tional 90-nucleotide exon corresponding to an 0-glyco- 
sylated region usually found in LDLRs has been 
identified. Interestingly, the longer transcript and protein 
are present at the highest levels in exactly those tissues 
that express VLDLRs in mammals, but the smaller pro­
tein is found almost exclusively in the gonads, ie, the 
ovary and testes. Second, Schneider and colleagues have 
demonstrated that OVR binds and internalizes a2M, hith­
erto known as a ligand of LRP only. Since «2M not only 
inactivates proteinases but also carries and/or modulates 
certain growth factors and cytokines, it appears that both 
types of germ cell utilize the smaller form of the receptor 
to obtain, in addition to lipoproteins, nonlipoprotein com­
ponents important for growth and differentiation. Thus, 
the evidence strongly suggests that OVR is involved in 
maturation of female and male germ cells. Third, the mu­
tation in OVR that causes atherosclerosis and female ste­
rility in an animal model of familial hypercholesterole­
mia, the “restricted ovulator” hen, has been determined. 
This is the first naturally occurring mutation in a receptor 
of the VLDLR group. Again, the failure of this mutant to 
reproduce links abnormal gonadal development to lipo­
protein metabolism and places OVR at a crucial position 
in the paths of lipoprotein metabolism and regulation of 
cell differentiation.
Roméo Cecchelli (Lille, France) reported that trans- 
cytosis of LDL across the blood-brain barrier appears 
to be a “new” function of the LDLR. In a coculture of 
astrocytes and brain capillary endothelial cells on op­
posite sides of a filter, evidence was found for a soluble 
factor that regulates LDL transcytosis, which appears 
to be driven by the cholesterol content of the astro­
cytes. Blocking this LDLR with the monoclonal anti­
body C7, which is known to interact specifically with 
the receptor-binding domain, abolished transcytosis of 
LDL. Radiolabeled LDL was not degraded during 
transcytosis, thereby indicating that this “new” path­
way is different from the classic LDLR pathway 
whereby LDL is directed to the lysosomes for degra­
dation. The use of filipin, a drug that disrupts caveolar 
trafficking, blocked LDL transcytosis to the endothelial 
cells, thus indicating involvement of the caveolae in 
the LDL transcytosis pathway.
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Selected Abbreviations and Acronyms
A-Imìiuih/A-II/A-I-K-O
a2M
AD
apoA-1 Miium/apo A-I I/apo A-I 
knockout mice 
ö2-macroglobulin 
Alzheimer’s disease
C7EBP-CV = CCAAT/enhancer binding
protein-a 
FH = familial hypercholesterolemia 
GPDH = glyceraldehyde 3-phosphate
'UTftnnyp
HL = hepatic lipase
HNF3
LCAT
hepatocyte nuclear factor-3
lecithin-cholesterol
aeyltranslerase
LPL =  lipoprotein lipase 
LPS = lipopolysaecharide 
LRP — LDL receptor-related protein 
MAP = microtubule-associated protein 
MNP-3 = mononuclear phagocyte-3
NAME
NMMA
nitroarginine methyl ester 
A^-monomethylarginine
OVR = oocyte vitellogenesis receptor
= platelet-activating factor 
(acetyl hydrolase)
PAF(AH)
RHDL = reconstituted HDL 
SAA = serum amyloid A 
(V)LDLR(s) = (V)LDL receptor(s)
WHHL = Watanabe heritable hyperlipidemic 
YAC = yeast artificial chromosome
Richard James (Geneva, Switzerland) presented data 
on injury-induced expression and release of apoE and 
apoJ (clusterin) from cultures of embryonic rat spinal 
cord neuronal cells. Within 24 hours of induction of lethal 
stress by glutamate treatment (specific for neurons), there 
was an increase in apoE and apoJ mRNA content and 
release of these apoproteins, both of which events could 
be blocked by the /V-methyl D-aspartate receptor antag­
onist MK-801. Both apoproteins were associated immu- 
nohistochemieally with neuronal and nonneuronal cells, 
and expression of apoE and apoJ in both cell types was 
also induced by nonspecific initiation of cell death. Given 
that both proteins are associated with the plaques of AD, 
these data may be relevant to the pathogenesis of this
'  O k  O  I ?  #.3fc
Winfried März (Freiburg, Germany) presented the re­
sults of a study of 200 histomorphologically staged AD 
brain samples, in which the c4 allele was correlated with 
the amount of amyloid in the brain and the formation of 
neurofibrillary tangles. In vitro studies of /3-VLDL-/3- 
amyloid 4 complexes, in which ¿0-amyloid 4 is associated 
with the apoB moiety of /3-VLDL, showed increases in 
uptake of the complexes, which subsequently were not
that LRP
could be the receptor responsible for uptake of these com­
plexes and that /3-amyloid 4 is the peptide that modifies 
intracellular trafficking of internalized ligands.
Markus Haumer (Vienna, Austria) reported on the co- 
staining of lactoferrin and apo E in brain slices from au- 
topsied patients with AD. Lactoferrin, a known ligand of 
the LRP, was recovered from the bloodstream into en- 
dosomes in an SDS-stable complex with LRP. Partici­
pation of lactoferrin under such conditions and at sites of 
inflammation was assumed from postmortem brain tissue
2 sclerosis. At acute inflam-sl ices of patients with 
matory foci, apoE-lactoferrin costaining was dramatically 
enhanced, preferentially within macrophages that had in­
filtrated activated glial cells. The cell-surface staining of 
macrophages disappeared at late-focus inflammatory sites 
with lactoferrin but not at those with apoE; lactoferrin 
stained at a single intracellular region, whereas apoE 
showed a staining pattern that resembled ongoing endo- 
cytosis. The interplay of apoE and lactoferrin, both li­
gands for the LRP, is being investigated further in tissue 
cultures of glia-supported neurons.
Armin Steinmetz (Vienna, Austria) gave an overview 
of the lipoprotein and nonlipoprotein functions of human 
apoA-IV. He presented new data that emphasized the un­
usual appearance of this hydrophilic plasma apoprotein, 
which is predominantly associated with pre-/?-migrating
in reverse
transport. ApoA-IV/phosphatidylcholine complexes and
apoA-IV-containing isolated from human
plasma are capable of promoting cellular cholesterol ef­
flux; pre-/3-migrating apoA-IV particles can serve as pri­
mary acceptors of cell-derived cholesterol, as shown by
two-dimensional gel Free (unbound)
cell-derived cholesterol can be esterified by the enzyme 
LCAT in the presence of apoA-IV as a cofactor. By using 
deletion mutants of the protein that are expressed in Esch­
erichia coli, the relevant domain in apo A-I V for cofactor 
activity can be localized between amino acids 117 and 
160. A novel function of apo A-I V that is not shared by 
apoA-I and appears distinct from other functions de­
scribed so far was reported by P. Tso and colleagues, 
namely, suppression of food intake in the rat by apoA-IV 
when infused intravenously or given intracerebroventric- 
ularly (J  Clin Invest. 1993;91:1830-1833.). ApoA-IV has
also been shown to decrease gastric acid secretion when 
given intracerebroventricularly. In a collaborative study 
with human apoA-IV, Tso and colleagues also observed 
suppression of food intake in rats. Subsequent studies of 
apoA-IV in human cerebrospinal fluid revealed migration 
of apoA-IV in the pre-/3 position and with the apparent 
same molecular mass and identical isoelectric focusing 
patterns as those of apoA-IV in plasma. Further evalua­
tion of this intriguing new function should concentrate on 
the processes by which apoA-IV reaches the structures of 
the central nervous system.
Richard Bruckdorfer (London, England) reported the 
inhibitory effects of LDL and HDL on thromboplastin
issoeialcd withactivity that were independent of 
tissue factor pathway inhibitor, a protein that, to a large 
extent, is bound to these lipoproteins. In the case of LDL,
activity was to reside in apoB-100,
although oxidation of the lipoprotein reversed this inhi-
and ultimately led to procoagulant activity exhib- 
by LDL. 1
showed the presence of both hydrophobic and ionic in­
teractions between apoB-100 and thromboplastin.
The following talk, by David Riddell (London, En­
gland), considered the influence of apoE on NO produc­
tion in platelets. ApoE-dimyristoylphosphatidylcholine 
complexes induced potent, dose-dependent inhibition of 
ADP-induced platelet aggregation in platelet-rich plasma
as as was
when the platelets were preincu­
bated with the NO synthase inhibitors l-NMMA and l -  
NAME (300 /¿mol/L) but not d-NMMA, Other experi­
ments supported the notion that apoE stimulates NO 
production: its physiological target guanylate cyclase was 
activated because cAMP levels rose. This is the first re-
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port to show that apoE influences NO production, al­
though it remains to be established whether this newly 
identified link between apoE and NO is widespread.
The session continued with a comprehensive overview 
of the acute-phase protein SAA by Patricia Woo (Lon­
don, England). This protein is secreted mainly by hepa- 
tocytes and its concentration can increase as much as 
1000-fold during inflammation. In the circulation SAA is 
associated primarily with HDL. The SAA superfamily 
comprises two acute-phase genes, SAA1 and SAA2; a 
pseudogene, SAA3; and a constitutive llpl5. Both SAA1 
and SAA2 are found in human amyloid deposits, whereas 
only SAA2 is found in amyloid deposits in B ALB/c mice. 
With the use of recombinant SAA and transfectant mu­
tants (Asp8 and 1-11 A), it has been demonstrated that the 
//-terminal region of SAA is important for HDL binding. 
This region also appears to be important for the incor­
poration of SAA into amyloid deposits, because in the 
CE/J mouse strain, which is resistant to amyloidogenesis, 
the major SAA isoform shows mutations in the /^-ter­
minal peptide. Furthermore, in a formation assay in vitro, 
the 1-11A transfection mutant was unable to form fibrils. 
From the work of several groups it is apparent that SAA 
functions may be important in atherosclerosis as well. 
Recombinant SAA has been shown to have high affinity 
for cholesterol, and SAA can enhance cholesterol efflux 
from HDL as well as stimulate uptake of radiolabeled 
cholesterol from the medium by HepG2 cells. Another 
property of recombinant SAA is its ability to inhibit 
thrombin-induced platelet aggregation. SAA mRNA has 
also been detected in endothelial cells, some smooth mus­
cle cells, and macrophage-derived foam cells from human 
atherosclerotic lesions.
In the next lecture Daniel M. Levine (New York, NY) 
discussed the ability of RHDL to neutralize endotoxin. 
The lipid A domain of LPS not only anchors it to Gram- 
negative bacteria but also inserts it into HDL. In a mouse 
lethality model it was shown that intravenous infusion of 
RHDL, which causes a twofold elevation in circulating 
HDL levels, led to a fourfold increase in survival com­
pared with control mice that received an intravenous in­
fusion of sahne only. Introduction of human APO A l into 
transgenic mice also caused a twofold elevation in HDL 
levels and a concomitant fourfold increase in survival. 
Furthermore, in high-HDL mice, tumor necrosis factor-a 
release was significantly lower than in low-HDL mice. 
The ability of RHDL, a lipid emulsion (Intralipid) with 
naturally occurring lipoproteins, to neutralize LPS was 
tested in an in vitro human whole-blood model of LPS
Human serum paraoxonase is an enzyme that is asso­
ciated with a specific HDL particle that contains apoA-I 
and apoJ. Michael Mackness (Manchester, England) re­
ported that purified paraoxonase is capable of preventing 
the accumulation of lipid peroxides in LDL that has been 
incubated under oxidizing conditions. PAFAH is active 
on both HDL and LDL and is also capable of hydrolyzing 
oxidized phospholipids. Paraoxonase was purified to ho­
mogeneity from human HDL and its ability to hydrolyze 
PAF was investigated. Although paraoxonase was able to 
hydrolyze PAF at a rate of 10 nmol • min_ 1 • kg ~ 1 with a 
K m of 10.1 /imol/L, its activity was «  1000-fold lower 
than that of LDL-associated PAFAH. Mackness and col­
leagues have postulated that both PAFAH and paraoxo­
nase may act in concert to hydrolyze lipid peroxides that 
are generated on LDL.
Ulrike Beisiegel (Hamburg, Germany) described the 
identification of a putative new apolipoprotein of 110 kDa 
that was initially detected during catabolic studies with 
125I-labeled chylomicrons. Digestion of the protein with 
trypsin and V8 yielded four peptides that have >80% 
homology with human complement factor H-related pro­
teins. After polyclonal antibodies had been generated 
against the purified protein, it was also detected in HDL. 
Incubation of human plasma with Intralipid and separa­
tion of the TG-rich lipoproteins by ultracentrifugation led 
to enrichment of this fraction with the 110-kDa protein. 
A HepG2 cDNA library is presently being screened with 
the polyclonal antibody to clone the gene for the 110-kDa 
protein.
The final talk of this session was given by Gregor Roth 
(Regensburg, Germany), during which he described char­
acterization of circulating blood monocyte subpopula­
tions by flow cytometry. Five subpopulations were iden­
tified on the basis of differential expression of CD 14, 
CD64, CD 16, CD32, CD33, and CD56. The distribution
of these monocyte subpopulations was studied in healthy 
probands (n=55) and patients with FH (n=19). HDL cho­
lesterol levels were negatively correlated with the size of 
the MNP-3 population in FH patients, and apo E3/3 and 
E4/4 phenotypes were associated with an increase in the 
MNP-3 population in healthy probands and FH patients. 
Expression of the CD45RA activation antigen by blood 
MNPs showed a positive correlation with plasma levels 
of LDL and Lp(a). Dr Roth suggested that systemic ab­
normalities in MNPs are related to the chronic inflam­
matory process within atherosclerotic lesions of the ves­
sel wall.
The second session of the meeting, “Innovative Ani-
binding protein and CD 14-dependent activation of cyto- mal Models for Lipoprotein Research: Transgenies,
kine production. Only phospholipid content was found to 
be correlated with the effectiveness of LPS neutralization.
Knockouts Towards Gene Therapy,” began with an ex­
cellent lecture by Edward Rubin (Berkeley, Calif) about
These data support the hypothesis that LPS binding to Lp(a) and its role in atherosclerosis. Lp(a) is present in
phospholipid on the surface of RHDL prevents CD 14- 
dependent activation of tumor necrosis factor-a.
Wie Liao (Huddinge, Sweden) investigated whether
endotoxin could alter LDLR expression in rats. Eighteen
hours after injection of 500 fig endotoxin per 100 g body
weight IP, LDLR expression had been reduced by 70%.
In contrast, LDLR mRNA levels were markedly higher
at this time point. Time-course experiments showed that
LDLR expression progressively decreased and that
mRNA levels decreased by 78% at 4 hours, returned to
baseline levels at 8 hours, and increased by «60% after 
18 hours.
humans, monkeys, and surprisingly the hedgehog but is 
absent in other species, which implies that the most fre­
quently used laboratory animals, ie, mice, rats, and rab­
bits, do not naturally have it. Use of DNA technology has 
made it possible to create animal strains that express 
apo(a). Transgenic mice that express human apo(a) have 
been bred, and expression of the gene is controlled by the 
promoter of another mouse gene. However, this method 
has created a problem for study of the regulation of apo(a) 
gene expression. Dr Rubin presented information on a 
YAC construct composed of 275 kb of human DNA that 
contains the entire apo(a) gene and >60 kb of the 5' and
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3' noncoding regions. After injection of this construct 
into fertilized mouse oocytes, four lines were obtained in 
which no rearrangement or fragmentation of the huge 
DNA fragment had occurred. Plasma levels of human 
apo(a) in these mice ranged from 8 to 40 mg/dL. The 
apo(a) mRNA was expressed only in the liver, indicating 
that the DNA construct contained all or most of its reg­
ulatory regions, at least with regard to tissue specificity.
Apo(a) has also been claimed to be an acute-phase pro­
tein. In Dr Rubin’s experiments an acute-phase reaction 
in apo(a)-transgenic mice was induced by injection of 
turpentine. As an indicator for the acute-phase reaction, 
haptoglobulin mRNA levels were found to have increased 
fivefold. However, there was no increase in the amount 
of apo(a) mRNA, indicating that apo(a) is not an acute- 
phase protein.
Apo(a) has also been claimed to be under hormonal 
control. Apo(a) mRNA levels were measured before and 
after orchiectomy in apo(a)-transgenic mice, and an ap­
proximate twofold to threefold increase in the amount of 
mRNA was observed after the procedure. This finding 
confirms that male hormones control expression of 
apo(a). Upregulation of apo(a) mRNA could be abolished 
by treating the animals with either testosterone or estro­
gen, and it was surprising that both hormones had a sim­
ilar effect on apo(a) expression.
Transgenic mice that express human apo(a) do not 
have Lp(a), because mouse LDL does not bind to apo(a). 
To construct Lp(a)-bearing mice, transgenic mice that ex­
pressed human apoB were made and then mated with 
transgenic mice that expressed human apo(a). Because 
only low-expressor apoB-transgenic mice were used, 
most of the human apoB was bound to human apo (a). 
The LDL-VLDL ratio was calculated in control, low-ex­
pressor human apoB-transgenic, human apo(a)-trans- 
genic, and Lp(a)-bearing mice. Relative to controls, the 
ratio was only slightly elevated in apoB-transgenic and 
Lp(a)-bearing mice and somewhat more elevated in 
apo(a)-transgenic mice. However, when atherosclerotic 
lesions were examined, apoB-transgenic mice had only 
slightly more lesions than did control mice, but human 
apo(a)-transgenic mice had an «  10-fold increase in le­
sions and those mice that expressed both human apo B 
and apo(a) had an «20-fold elevation in lesion area com­
pared with controls. These findings indicate that free 
apo(a) per se is an atherogenic protein and that apo(a) 
bound to LDL is even more atherogenic.
Dr Rubin also presented data on apo(a)-human apoB 
interactions, which are known to be due to a disulfide 
bond. In apo(a) the Cys at amino acid 4057 is known to 
be involved in disulfide bonding, but in apoB there are 
four Cys’s at the carboxy-terminal end (at amino acids 
3734, 3890, 4190, and 4326) that are potential sites for 
disulfide bonding. Dr Rubin showed that when the Cys 
at position 4326 was altered, all apo(a) was lipid-free, 
indicating that this Cys is the one responsible for the di­
sulfide bond between apo (a) and apoB.
In the final part of his lecture, Dr Rubin discussed the 
consequences of enhanced apoB editing on Lp(a)-bearing 
mice. Protein p27 has been shown to cause the C—>U 
change in apoB mRNA that results in the manufacture of 
apoB-48 instead of apoB-100. An adenovirus construct 
that contained the p27 gene was injected into rabbits. 
These animals do not normally edit apoB, but after injec­
tion with the p27 construct, the rabbits were found to have
apo B-48 in their plasma. When the same construct was 
injected into Lp(a)-transgenic mice, plasma levels of 
Lp(a) were found to be only one fifth of their original 
values. This means that by altering apoB editing, it is 
possible to lower the amount of apoB-100-containing 
LDL in plasma, which would in turn make the lipoprotein
profile less atherogenic.
The next speaker, Francisco Blanco-Vaca (Barcelona, 
Spain), presented his work on human apoA-II in three 
transgenic mouse lines with plasma concentrations of 
apoA-II ranging from 21.4 to 74.4 mg/dL. In these mice, 
human apoA-II was expressed exclusively in the liver and 
the protein was found only in HDL particles. When mice 
of the highest-expressor line were fed a standard chow 
diet, mRNA levels for mouse apoA-I and A-II decreased. 
However, when these mice were kept on a high-fat diet, 
no decrease in mRNA levels was observed. Serum total 
cholesterol levels decreased and TG levels increased 
when the mice were fed the chow diet. Lipoprotein anal­
ysis revealed that the increase in TGs was due to an in­
crease in VLDL TGs and that the decrease in total cho­
lesterol was due to a decrease in HDL cholesterol. When 
the mice were kept on the high-fat diet, HDL cholesterol 
levels in control mice decreased, but those in high- 
expressor apo A-II—transgenic mice increased. Potential 
mechanisms for this paradoxical rise were discussed.
Giulia Chiesa (Milan, Italy) presented studies on trans­
genic mice that express the human variant apoA-IMil.ano*
which is characterized by a Cys-*Arg substitution at po­
sition 173. Carriers of this apo A-I variant have dramati­
cally lower HDL cholesterol levels but an apparent sur­
prising absence of cardiovascular disease. ApoA-íM¡ian» is 
known to exist as a homodimer as well as a heterodimer 
with human apoA-II. Since mouse apoA-II does not form 
a heterodimer with apoA-IM¡iam» mice that express both 
human apoA-IMiiano and human apo A-II were created. To 
better evaluate the effects of apoA-IM¡inm.> these double- 
transgenic mice were then mated with apoA-I—knockout 
mice, resulting in A-IM¡i0nc/A-II/AI-KO. Mice that ex­
pressed human apoA-I and A-II on an apoA-I knockout 
background were used as controls. The A-IMiUmo/A-II/AI- 
KO had higher serum TG levels and lower HDL choles­
terol levels. HDL was present in two subclasses, as it is 
in humans, and the size and density of HDL particles 
resembled that of human HDL. In these A-lMiUMn/A-II/AI- 
KO, apoA-IMiiano formed homodimers and heterodimers 
as it does in human plasma. With this new mouse line the 
effects of apo A-IMiiam> can t>e studied in greater detail.
Anja Mehlum (Oslo, Norway) presented a study on 
human LCAT-transgenic mice. A high-expressor human 
LCAT-transgenic mouse line was created, and LCAT ac­
tivity in these mice was «40-fold higher than normal. 
This overexpression of LCAT resulted in decreased se­
rum TG levels. Although LPL activity remained un­
changed, HL activity increased markedly. LDL and 
VLDL cholesterol levels decreased while HDL choles­
terol increased by «20%  and the size of HDL particles 
also increased by «20% . Cholesterol efflux—stimulating 
activity of HDL from these transgenic mice was nearly 
doubled when compared with controls. Most likely, these 
LCAT-transgenic mice have a less atherogenic lipopro­
tein profile than do control mice.
Omar Francone (Groton, Conn) discussed studies of 
transgenic mice that express a moderate increase in 
LCAT activity (1.2- to 1.6-fold of the normal value). A
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20% to 60% increase in HDL cholesterol was also ob­
served. These LCAT-transgenic mice were mated with 
human apoA-I- and/or human apoA-II—transgenic mice, 
thereby producing three mouse lines. HDL cholesterol 
levels were twofold higher and the HDL particle size was 
larger in apoA-I/LCAT- and apoA-I/apoA-II/LCAT- 
transgenic mice compared with apoA-I-, apoA-II/ 
LCAT-, and LCAT-transgenic mice.
Catherine Fievet (Lille, France) presented a study of 
transgenic rabbits. Six transgenic lines were obtained af­
ter injection of a 12.5-kb DNA fragment (containing the 
entire human apoA-I gene) into oocytes from New Zea­
land White rabbits. The level of human apo A-I was 8 to 
100 mg/dL and the level of rabbit apoA-I was reduced. 
In the highest-expressor line, HDL cholesterol levels in­
creased from 18 to 49 mg/dL and total cholesterol from 
46 to 76 mg/dL. HDL appeared in only one size fraction, 
as in control rabbits, and not in two size fractions, as in 
humans and transgenic mice that express human apoA-I. 
There was a linear correlation between plasma human 
apoA-I and HDL cholesterol levels. These transgenic rab­
bits were then mated with the LDLR-deficient WHHL 
rabbit. Levels of human apo A-I were «100 mg/dL in 
these offspring and their HDL levels were significantly 
higher than in the LDLR-deficient rabbits. The non-HDL 
cholesterol to HDL cholesterol ratio was fourfold lower 
in WHHL rabbits carrying the human apoA-I gene com­
pared with control WHHL rabbits. In WHHL rabbits ex­
pression of human apo A-I did not decrease the expression 
of rabbit apoA-I.
Marten Hofker (Leiden, Netherlands) presented studies 
about mice deficient in both apoE and apoC-I. The genes 
for these proteins are located in a conserved cluster in 
both humans and mice. Mice that lack both genes cannot 
be obtained by mating because of the proximity of the 
genes. This problem was overcome by consecutive tar­
geting. First, the apoE gene was replaced by that for neo­
mycin resistance; then these embryonic stem cells (lack­
ing apoE) were targeted with a construct in which the 
apoC-I gene had been disrupted with a hygromycin gene. 
ApoE, C-I, and C-II probably share common regulatory 
regions. In mice that lacked both apoE and apoC-I, ex­
pression of apoC-II was also affected and was only 
*=¡60% of normal. Mice that lack apoE only have «68% 
of normal apoC-I mRNA levels, and in those that lack 
apoC-I the amount of apoE mRNA is decreased by 50%.
Francesco Acquiati (Mannheim, Germany) presented 
work about apo(a) expression. To obtain the very large 
apo(a) gene and its flanking regions, YAC clones had to 
be used. Because different apo(a) alleles have very dif­
ferent expression activities and because high levels of 
apo(a) expression were needed, a YAC library was con­
structed with material from a subject who had a high 
plasma level of apo(a); this allele was subsequently 
cloned. This 370-kb fragment contained the entire apo(a) 
gene and 40 kb of the 5' and 150 kb of the 3' flanking 
sequences. When this construct was microinjected into 
mouse oocytes, one transgenic line expressing human 
apo(a) was obtained. The integrated DNA construct did 
not contain any structural rearrangements.
The second half of this session began with a presen­
tation by Seppo Ylä-Herttuala (Kuopio, Finland). He 
gave an excellent review about the techniques that are 
used in gene therapy and the problems that are associated 
with these techniques. Retroviruses, the most widely used
vectors in gene therapy, are RNA viruses in which struc­
tural genes between two long tandem repeats can be re­
placed by the gene of interest. Retroviruses become in­
tegrated with chromosomal DNA and therefore, their 
expression is stable. However, mitosis is required for ret­
roviral material to be incorporated, which implies that 
there is a potential danger for insertional mutagenesis, 
although so far no reports of this have appeared. Another 
problem with retroviruses is size restraint, since only 7 to 
8 kb can be inserted into a retrovirus construct.
Adenoviruses have great potential for use in gene ther­
apy. They infect a wide variety of cells and no mitosis is 
needed for incorporation of adenoviral material. One lim­
itation is that they do not become integrated with the ge­
nomic DNA, and thus their expression is only transient. 
On the other hand, because there is no integration, there 
is no danger of insertional mutagenesis. Adenoviruses 
may cause problems with the immune response because 
repeated adenovirus infections will have no effect. At 
present third-generation adenovirus vectors are available, 
but these vectors cannot yet be used in the treatment of 
chronic diseases. Liposomes are safe vectors, since they 
do not contain any viral DNA. They do not integrate and 
thus, there is no danger of insertional mutagenesis. Be­
cause there is no integration their expression is only tran­
sient, and the transfection efficacy of liposomes is poor. 
These liposomal vectors could be used in situations in 
which transient expression or inefficient transfection is 
sufficient, such as for treatment of restenosis after 
angioplasty.
Wolfgang Hofmann (Graz, Austria) discussed trans­
genic mice that express human LPL. LPL is produced 
primarily in cardiac and skeletal muscle and adipose tis­
sue. Tissue-specific expression of LPL was studied with 
a DNA construct that contained either 4.6 or 8.0 kb of 
the upstream region of the mouse LPL gene linked to a 
human LPL minigene. Mouse lines in which the 4.6-kb 
construct was integrated did not express human LPL at 
all. Lines that contained the 8.0-kb construct had a high 
level of human LPL expression in cardiac muscle only. 
When these transgenic mice were mated with LPL knock­
out mice, TG levels in their offspring were dramatically 
reduced; mice homozygous for the LPL deficiency and 
without human LPL died during the first day of life, 
whereas mice homozygous for the mouse LPL deficiency 
but with human LPL expression in cardiac muscle sur­
vived. These transgenic mice demonstrate that it is suf­
ficient to have LPL expression in only one tissue to con­
trol plasma TG levels.
Peter Weinstock (New York, NY) also presented a 
study on LPL knockout mice, in which the endogenous 
L P L  gene had been replaced by a neomycin resistance 
gene. At birth homozygotes for the LPL deficiency had 
threefold and sevenfold elevations in TG and VLDL cho­
lesterol levels, When allowed to suckle
these mice died 18 hours after birth. At that time their 
TG levels were «  15 000 mg/dL (188 mg/dL in controls). 
The reason for premature death in these mouse pups is 
most likely chylomicron inhibition of contact between red 
blood cells and the endothelium in lung capillaries, thus 
preventing normal gas exchange. I-Ieterozygotes for LPL 
deficiency survived to adulthood but had mild hypertri­
glyceridemia. VLDL turnover studies revealed a decrease 
in VLDL clearance but no increase in VLDL production.
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Thus, in mice a complete LPL deficiency is lethal and a 
partial LPL deficiency has physiological consequences.
The last talk in this session was given by Jesus Osada 
(Zaragoza, Spain) on HL knockout mice. Mice homozy­
gous for this deficiency had mild hypercholesterolemia, 
but their TG levels were not altered. On a high-fat diet 
the HDL cholesterol level was about doubled in HL 
knockout mice, whereas it was slightly less than normal 
in controls. These findings demonstrate that HL has an 
important role in HDL metabolism.
The third session on “Fatty Acid Metabolism: Regu­
lation and Clinical Implications” began with a compre­
hensive overview by Peter Arner (Huddinge, Sweden) on 
adipocyte lipolysis. It is well established that adipose tis­
sue is a heterogeneous metabolic organ. Lipid mobiliza­
tion via lipolysis in fat cells is more pronounced in vis­
ceral fat depots than in peripheral subcutaneous regions. 
This difference can be attributed to regional changes in 
the action of the major lipolysis-regulating hormones, 
catecholamines and insulin. Catecholamines are more and 
insulin is less lipolytic in visceral compared with subcu­
taneous fat cells. The catecholamine difference is attrib­
uted to changes in the expression and function of adre­
nergic receptors. The lipolytic ß\, 02, and /33-adrenergic 
receptors are more prominent in visceral fat cells, 
whereas the antilipolytic actions of a2-adrenergic recep­
tors are more pronounced in subcutaneous cells. Insulin 
is less lipolytic in visceral fat cells because of a com­
bination of decreased receptor affinity and decreased 
signaling through the phosphatidylinositol kinase 3 
pathway.
Dr Arner went on to discuss the metabolic (insulin re­
sistance) syndrome, in which elevated levels of free fatty 
acids are commonly observed. This may be partially due 
to a further increase in the regional differences in lipol­
ysis. Catecholamine action is inhibited in subcutaneous 
fat cells owing to a decrease in the expression and func­
tion of the /?2-adrenergic receptor plus a decrease in the 
final rate-limiting step of lipolysis activation by hormone- 
sensitive lipase. However, catecholamine action on lipol­
ysis is increased in visceral fat cells owing to an increase 
in function of the 03 -adrenergic receptors combined with 
a decrease in function of the a2-adrenergic receptors. 
These concurrent processes enhance lipid mobilization 
from visceral fat cells and decrease lipid mobilization 
from subcutaneous fat cells after catecholamine stimula­
tion in the metabolic syndrome. Thus, portal levels of free 
fatty acids will be markedly elevated, and these in turn 
can cause a number of the metabolic changes that are 
typically observed in the syndrome, such as hyperinsu-
increased VLDL TG production, and increased
Finally, Dr Arner discussed another condition in which 
itions in adipocyte lipolysis may be important, 
namely, familial combined hyperlipidemia. He pointed 
out that this condition is associated with lipolytic cate- 
amine resistance in subcutaneous fat cells owing to 
a selective defect in expression of hormone-sensitive lip­
ase. In addition, the ability of fat cells to synthesize TGs
pose tissue is “uncoupled” from normal VLDL metabo­
lism, then the capacity of other pathways to accommodate 
the increased VLDL “traffic” may be insufficient, so that 
VLDL may accumulate in the blood and cause 
hypertriglyceridemia.
Gunnar Bjursell (Göteborg, Sweden) described the mo­
lecular mechanisms of adipocyte differentiation. Mature 
adipocytes arise from multipotent stem cells. After deter­
mination adipoblasts are formed, which then develop into 
preadipocytes that express early markers of the adipocyte 
phenotype. Subsequent differentiation leads to establish­
ment of adipocytes that express late markers for fat cell 
development. Dramatic changes in cell morphology and 
gene expression occur during development. Late events 
in adipogenesis include activation of many adipocyte- 
specific genes. The transcription factor C/EBP-o: has been 
shown to transactivate a number of such genes. By cul­
turing 3T3-F442A preadipocytes with or without the two 
adipogénie hormones insulin and hydrocortisone, Dr 
Bjursell could monitor the gradual activation of C/EBP- 
a as well as one early marker, LPL, and one late marker, 
GPDH, for adipocyte differentiation under different con­
ditions. Hydrocortisone treatment prevented development 
of the adipocyte phenotype as well as expression of
GPDH and C/EBP-a. Stably transfected 3T3-F442A 
preadipocytes with an “antisense” C/EBP-a: expression 
plasmid reduced lipid accumulation after the cells had 
differentiated into mature adipocytes. Lipid accumulation 
appeared to be correlated in a linear manner with the level 
of C/EBP-a protein.
LPL is one of the first markers of adipocyte differen­
tiation. Transient transfection studies by Bjursell’s group 
revealed the existence of several positive and negative 
elements in the LPL promoter. Possible regulatory ele­
ments were also identified in the introns and the 3' flank­
ing sequences by a DNase I hypersensitivity assay. Stable 
transfection of different 5' deletion mutants in 3T3- 
F442A preadipocytes was established, and gradual 
activation of the LPL promoter during preadipocyte dif­
ferentiation was monitored by chloramphenicol acetyl- 
transferase assays at different times. Two regions, named 
LP-a and LP-0, were found to be necessary for differ­
entiation-linked activation of the LPL promoter. Previ­
ously unidentified members of the HNF3/forkhead tran­
scription factor family were shown to interact with motifs 
in LP-a and LP-/3. This is the first example of the in­
volvement of HNF3/forkhead members in regulating adi­
pocyte-specific gene expression.
The role of fatty acids as products or regulators of li­
poprotein metabolism was discussed further in this ses­
sion. Long-chain fatty acids can modulate the expression 
of LPL in adipocytes cultured in vitro by increasing tran­
scription levels while decreasing the levels of activity and 
secretion (Gérard Ailhaud; Nice, France). This effect was 
dependent on the type of fatty acid: absent with short- or 
medium-chain fatty acids, but increasing with the length 
of long-chain fatty acids. According to Martin Bergö 
(Umea, Sweden) LPL synthesis in rat adipose tissue mod­
ulates most of the LPL activity at basal levels, whereas
is impaired. The combination of these two defects causes during short-term fasting/feeding periods
1  .  _____ ,  1 1  . 1 .  * ^ ___________  ______  •  i l  ,  1  . 1  Va decrease in TG turnover in fat cells, which in turn may 
lead to a situation in which adipose tissue is “un­
coupled” from the route whereby free fatty acids in 
VLDL are stored in and then released from fat to be taken 
up by the liver for synthesis of new VLDL TGs. If adi-
nisms that completely suppress LPL activity operate at 
the posttranscriptional level.
In humans levels of fatty acids that are released by adi­
pose cells in subcutaneous veins have been shown to reflect 
VLDL production and to be correlated with plasma TG and
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apoB levels (Simon Coppack; London, England). More­
over, in postprandial periods after sequential meals, nones- 
terified fatty acids released by LPL from chylomicrons pro­
duced after the second meal were found to have originated 
from TGs produced after the first meal (Keith Frayn; Ox­
ford, England). On the other hand, unsaturated fatty acids 
were the most potent stimulators of lipoprotein secretion 
when added to either cultured CaCo cells (Marleen van 
Greevenbroek; Utrecht, Netherlands) or primary cultured 
chicken hepatocytes (Philippe Legrand; Rennes, France) 
compared with saturated fatty acids. Furthermore, increases 
in A9-desaturase activity seemed to correlate with increases 
in VLDL production in this latter model. Fatty acids also 
could modulate T-lymphocyte activation in vitro (Thomas 
Stuling; Vienna, Austria). In humans a DNA variant 
(Asn29 ]- >Ser) that alters LPL activity has been found in co­
horts of subjects with angiographically assessed coronary 
artery disease. This variant appeared even more frequently 
in subjects with the phenotype of familial combined hyper- 
lipidemia (Taco Bruin; Amsterdam, Netherlands).
Philippe Moulin (Lyon, France) presented a case of 
autoimmune LPL deficiency. In this patient anti-LPL im­
munoglobulins were detected bound to LPL on the sur­
faces of circulating chylomicrons.
The 19th Annual Meeting of the European Lipoprotein 
Club is scheduled for September 9th to 12th, 1996, in
Tutzing, Germany. It will begin with a state-of-the-art
lecture on gene therapy, followed by three sessions that 
will examine ( 1 ) the genetics of lipoprotein disorders, (2) 
lipoproteins and the kidney, and (3) causes and conse­
quences of the metabolic syndrome. For information 
please contact Prof Guido Franceschini, Secretary, Eu­
ropean Lipoprotein Club, Centro E. Grossi Paoletti, In­
stitute of Pharmacological Sciences, Via Balzaretti 9, 
20133 Milan, Italy. Fax: 39/2/6470594.
The European Lipoprotein Club 
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INSERM, Paris, France; David Bowyer, University of 
Cambridge, Cambridge, England; Hans Dieplinger, Uni­
versity of Graz, Graz, Austria; Guido Franceschini, Insti­
tute of Pharmacological Sciences, Milan, Italy; Steve 
Humphries, Rayne Institute, London, England; Luis Ma- 
sana, Facilitai de Medicina, Reus, Spain; Anton Stalenhoef, 
University Hospital Nijmegen, Nijmegen, Netherlands; 
and Armin Steinmetz, Medizinische Klinik, Philipps- 
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